These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 8637045)

  • 1. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.
    Thalmann GN; Sikes RA; Chang SM; Johnston DA; von Eschenbach AC; Chung LW
    J Natl Cancer Inst; 1996 Jun; 88(12):794-801. PubMed ID: 8637045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
    Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
    Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Beraldi E; Sullivan LD
    Cancer Res; 1997 Apr; 57(8):1584-9. PubMed ID: 9108464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells.
    Wu HC; Hsieh JT; Gleave ME; Brown NM; Pathak S; Chung LW
    Int J Cancer; 1994 May; 57(3):406-12. PubMed ID: 8169003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
    Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
    Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model.
    Gleave ME; Sato N; Sadar M; Yago V; Bruchovsky N; Sullivan L
    J Cell Biochem; 1998 Jun; 69(3):271-81. PubMed ID: 9581866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.
    Hsieh JT; Wu HC; Gleave ME; von Eschenbach AC; Chung LW
    Cancer Res; 1993 Jun; 53(12):2852-7. PubMed ID: 7684949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-tocopheryl succinate (alpha-TOS) modulates human prostate LNCaP xenograft growth and gene expression in BALB/c nude mice fed two levels of dietary soybean oil.
    Basu A; Grossie B; Bennett M; Mills N; Imrhan V
    Eur J Nutr; 2007 Feb; 46(1):34-43. PubMed ID: 17180484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
    Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
    J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
    Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
    Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model.
    Sato N; Gleave ME; Bruchovsky N; Rennie PS; Goldenberg SL; Lange PH; Sullivan LD
    J Steroid Biochem Mol Biol; 1996 May; 58(2):139-46. PubMed ID: 8809195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
    Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
    Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet.
    Wang Y; Corr JG; Thaler HT; Tao Y; Fair WR; Heston WD
    J Natl Cancer Inst; 1995 Oct; 87(19):1456-62. PubMed ID: 7545759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
    Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
    Igawa T; Lin FF; Lee MS; Karan D; Batra SK; Lin MF
    Prostate; 2002 Mar; 50(4):222-35. PubMed ID: 11870800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.